Skip to main content

Table 2 Clinical and demographic characteristics of included patients

From: Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa

 

Included patients (n = 91)

Age, years*

67 (24–88)

Male sex, n (%)

66 (72.5)

APACHE II*

11 (2–28)

Co-morbidities, n (%):

 Malignancy

14 (15.4)

 Cardiovascular

26 (28.6)

 Pulmonary

33 (36.3)

 Diabetes Mellitus

21 (23.1)

 Urogenitala

14 (15.4)

 Hepatic

8 (8.8)

 Haematologicalb

12 (13.2)

 Neurologicalc

18 (19.2)

Charlson score*

4 (0–10)

McCabe score**

1.48 ± 0.64

Patients with CKD1 at baseline

19 (20.9)

Type of infection, n (%):

 Pneumonia

24 (24.6)

 Urinary tract infection

22 (24.2)

 Skin and soft tissue infection

11 (12.1)

 Organ space surgical site infection

10 (11)

 Bacteremia

6 (6.6)

 Other

18 (19.8)

 Hospital-acquired infection, n (%)

86 (94.5)

Department of hospitalization:

 Medical

44 (48.2)

 Surgical

32 (35.2)

 ICU2

15 (16.2)

Admission diagnosis category:

 Infection

26 (28.6)

 Other-medical

35 (38.5)

 Other-surgical

30 (33)

CMS3 daily dose (millions of IU4)**

5.45 ± 2.21

CMS3 total dose (millions of IU4)**

108.36 ± 96.41

CMS3 duration of treatment, days**

20.18 ± 16.01

Inhaled CMS3, n (%)

14 (15.4)

Combined antimicrobial therapy, n (%)

46 (50.5)

Css 5 (mg/L)**

1.67 ± 1.42

Css 5 > 1.28 (mg/L), n (%)

46 (50.5)

Css 5/MIC6**

3.43 ± 2.91

AKI7 prior to CMS3 treatment, n (%)

12 (13.2)

Patients with AKI at day 7, n (%)

 R (Risk)

19 (20.9)

 I (Injury)

9 (9.9)

 F (Failure)

2 (2.2)

Patients with AKI7 at the EOT8, n (%)

 R (Risk)

12 (13.2)

 I (Injury)

27 (27.7)

 F (Failure)

10 (11)

Clinical response, n (%)

72 (79.1)

30-Day all-cause mortality, n (%)

28 (30)

Hospital length-of-stay (days)*

67 ± 53.97

  1. 1 CKD chronic kidney disease, 2 ICU intensive cure unit, 3 CMS colistin methanesulphonate, 4 IU international units, 5 C ss colistin plasma concentration at steady-state, 6 MIC minimal inhibitory concentration, 7 AKI acute kidney injury, 8 EOT end of treatment
  2. *median (range)
  3. **mean ± SD
  4. aAmong urogenital co-morbidities were, renal disease, kidney stones and obstructive uropathy
  5. bAmong haematological co-morbidities were haemopoietic and lymphoreticular malignances
  6. cAmong neurological co-morbidities were Alzheimer’s disease, stroke, miastenia gravis, sclerosis and any kind of dementia